trial
as of 2026-07-01The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia
NCTId NCT06270108
at a glance
Early Phase 1 · Unknown
Enrollment 288 (estimated)
Sponsored by King's College London
Primary completion 2024-12-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Early Phase 1
Status
Unknown
Enrollment
288 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2022-11-14
Primary completion
2024-12-31
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
King's College LondonLead Sponsor
South London and Maudsley NHS Foundation TrustCollaborator
Investigators
1
Oliver D HowesPrincipal Investigator
Sites
1 total
London, United Kingdom
Facts & assertions
4 sourced
Enrollment
288
Phase
EARLY_PHASE1
Primary Completion Date
2024-12-31
Status
UNKNOWN
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication
indication
indication
indication
investigator
person